news biotech MacroGenics margetuximab beats Herceptin in phase 3

#news #biotech MacroGenics’ margetuximab beats Herceptin in phase 3

10:36 EST 6 Feb 2019 | Biotech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: MacroGenics’ margetuximab beats Herceptin in phase 3 .A phase 3 trial of MacroGenics’ margetuximab in HER2-positive metastatic breast cancer patients has met its primary endpoint. The anti-HER2 antibody … Continue reading

Original Article: #news #biotech MacroGenics’ margetuximab beats Herceptin in phase 3

More From BioPortfolio on "#news #biotech MacroGenics’ margetuximab beats Herceptin in phase 3"